Peptide questions · VIP
VIP side effects: what studies and users report
Reviewed Evidence: ModeratePublished by PepVault
The side effects most commonly reported for VIP are flushing, hypotension at higher doses and headache, among 4 the library lists; the library’s evidence on it includes controlled trials in people.
The library holds no separate safety note for VIP.
What is commonly reported with VIP
- Flushing
- Hypotension at higher doses
- Headache
- Lightheadedness
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 18) |
|---|---|
| Flushing | None: listed for VIP alone |
| Hypotension at higher doses | None: listed for VIP alone |
| Headache | 6: TB-500, Thymosin Beta-4, Linaclotide, ARA-290 and 2 more |
| Lightheadedness | None: listed for VIP alone |

Which VIP side effects the healing & recovery group shares
Across the 19 healing & recovery compounds in the library, the effects listed most often are headache (7 of 19), injection site reaction (7 of 19), nausea (rare) (7 of 19) and fatigue (6 of 19). VIP shares 1 of its 4 listed effects with at least one other healing & recovery compound; flushing, hypotension at higher doses and lightheadedness are listed for VIP alone.
Where the VIP reports come from
The library rates the evidence on VIP as moderate: animal studies plus some human data.
Of the library’s 5 research notes on VIP, 2 rest on clinical data and 3 on community reports.
Our 5 study pages on VIP: 2 randomized trials, 1 observational study and 2 clinical trials.
So VIP has controlled trials in people to set its listed effects against.
What our VIP study pages report on safety
VIP (aviptadil): discharge at 7.8 vs 10 days in COVID-19
Randomized trial, human, 2025: Deaths were 5.1% with aviptadil and 12.2% with placebo, and no patient dropped out because of side effects. In one small human trial, inhaled aviptadil added to standard care was well tolerated and tied to shorter hospital stays and better lung CT scores in COVID-19 patients.
VIP (aviptadil) missed its main goal in critical COVID-19 trial
Randomized trial, human, 2022: In subgroups, patients on high-flow nasal oxygen at the start were more likely to reach the main goal (p = 0.039), and those on mechanical ventilation had 10-fold higher odds of survival with the drug (p = 0.031); the team saw no drug-related serious side effects.
Questions people ask
What are the side effects of VIP?
The side effects most commonly reported for VIP are flushing, hypotension at higher doses and headache, among 4 the library lists; the library’s evidence on it includes controlled trials in people.
Do VIP’s side effects come from human studies?
The library rates the evidence on VIP as moderate, and the library’s evidence on it includes controlled trials in people.
Which VIP side effects are its own?
Among the healing & recovery compounds, the library lists flushing, hypotension at higher doses and lightheadedness for VIP alone.